Mariner LLC Decreases Stake in Edwards Lifesciences Co. (NYSE:EW)

Mariner LLC cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 452,269 shares of the medical research company’s stock after selling 19,782 shares during the quarter. Mariner LLC’s holdings in Edwards Lifesciences were worth $33,482,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. Crowley Wealth Management Inc. bought a new position in Edwards Lifesciences in the 4th quarter worth approximately $26,000. Millstone Evans Group LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth $30,000. Roble Belko & Company Inc purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $46,000. Finally, Catalyst Capital Advisors LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth about $54,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $70.63 on Wednesday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a market cap of $41.52 billion, a price-to-earnings ratio of 10.13, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average price of $71.27 and a 200-day moving average price of $70.76.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In related news, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the transaction, the chief executive officer now directly owns 59,083 shares in the company, valued at $4,106,859.33. This trade represents a 9.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 72,353 shares of company stock worth $5,197,442 over the last 90 days. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

EW has been the topic of several analyst reports. Evercore ISI decreased their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday, February 12th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Royal Bank of Canada restated an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Truist Financial dropped their price target on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a research report on Friday, April 11th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $78.55.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.